Stock NUVL NUVALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Nuvalent, Inc.

Equities

NUVL

US6707031075

Real-time Estimate Cboe BZX
Other stock markets
 12:48:48 03/05/2024 am IST 		5-day change 1st Jan Change
73.02 USD +3.35% Intraday chart for Nuvalent, Inc. +10.37% -0.91%
01/05 Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing MT
17/04 Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
AQ
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PR
Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones
AQ
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
AQ
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series, Oncology Day
AQ
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
PR
Nuvalent Announces Pricing of Public Offering of Common Stock
PR
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
AQ
Nuvalent Announces Public Offering of Common Stock
PR
Nuvalent, Inc. - Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile
AQ
Nuvalent to Participate in Upcoming September Investor Conferences
PR
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
AQ
Nuvalent to Participate in Upcoming August Investor Conferences
PR
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
PR
NUVALENT, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days
PR
NUVALENT, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
NUVALENT, INC. : Regulation FD Disclosure (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NUVL Stock
  4. News Nuvalent, Inc.
  5. Press Releases